Related Experiment Video
Updated: Apr 30, 2026
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Metastatic Renal Cancer: What Role for Everolimus?
Franck A Belibi1, Charles L Edelstein1
1Division of Renal Diseases and Hypertension, University of Colorado Denver, Aurora, CO, USA.
Abstract:
Metastatic renal cell carcinoma is uncommon (only 3% of cancers worldwide) but of poor prognosis. Renal cell carcinoma has traditionally been treated with cytokines (interferon-α or interleukin-2). More recently, a more clear understanding of the molecular and cellular mechanisms of the disease, involving the VEGF receptor and mTOR, has led to the discovery of novel therapies. Therapeutic options in patients with advanced RCC include the VEGF receptor inhibitors Sunitinib and Sorafenib, the anti-VEGF monoclonal antibody Bevacizumab and the mTORC1 inhibitors Temsirolimus and Everolimus. In 2009, Everolimus was FDA-approved for the treatment of patients with advanced clear cell RCC which had progressed within 6 months of stopping treatment with Sunitinib or sorafenib, or both drugs. Everolimus resulted in a 70% reduction in the risk of disease recurrence or death. The purpose of this review is to update on the current knowledge of the role of Everolimus in metastatic renal cell carcinoma.
Insights
Everolimus offers a new treatment for advanced metastatic renal cell carcinoma (RCC). This targeted therapy significantly reduces the risk of disease recurrence or death in patients with this uncommon but aggressive cancer.
Area of Science:
- Oncology
- Molecular Medicine
- Pharmacology
Background:
- Metastatic renal cell carcinoma (RCC) is rare and has a poor prognosis.
- Traditional treatments for RCC include cytokines like interferon-α and interleukin-2.
- Advances in understanding molecular pathways, including VEGF receptor and mTOR, have introduced novel therapies.
Purpose of the Study:
- To review the current knowledge on the role of Everolimus in treating metastatic renal cell carcinoma.
- To update on the efficacy and application of Everolimus in advanced RCC.
- To highlight Everolimus as a key therapeutic option for refractory RCC.
Main Methods:
- Review of existing literature and clinical trial data on Everolimus in metastatic RCC.
- Analysis of molecular targets and mechanisms of action for targeted therapies.
- Examination of FDA-approved indications and treatment guidelines for advanced RCC.
Main Results:
- Everolimus is an mTORC1 inhibitor approved for advanced clear cell RCC.
- It is indicated for patients progressing after treatment with VEGF receptor inhibitors (Sunitinib, Sorafenib).
- Everolimus demonstrated a 70% reduction in the risk of disease recurrence or death.
Conclusions:
- Everolimus is an effective targeted therapy for advanced metastatic renal cell carcinoma.
- It provides a significant survival benefit for patients who have progressed on prior therapies.
- The review emphasizes the importance of mTORC1 inhibition in managing advanced RCC.
More Related Videos
11:27Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
Published on: April 29, 2014
06:00Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines
Published on: September 13, 2017
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
02:38Mitogens and the Cell Cycle
01:27Tumor Immunotherapy